A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS. - Katz JS; Rothstein JD; Cudkowicz ME; Genge A; Oskarsson B; Hains AB; Chen C; Galanter J; Burgess BL; Cho W; Kerchner GA; Yeh FL; et al. (Annals of clinical and translational neurology, 2022)